Publications by authors named "Ingrid Bos-Sanders"
Article Synopsis
- Metronidazole has been the primary treatment for Clostridioides difficile infections, but resistance has been observed, sometimes due to a specific plasmid (pCD-METRO) and other unknown factors.
- Researchers aimed to uncover additional causes of resistance that do not rely on plasmids by examining various clinical isolates of C. difficile.
- The study revealed that almost all isolates exhibited increased resistance to metronidazole in the presence of haem and identified a genetic mutation in the hsmA gene associated with metronidazole resistance, highlighting the importance of haem in this resistance mechanism.
Metronidazole was until recently used as a first-line treatment for potentially life-threatening Clostridioides difficile (CD) infection. Although cases of metronidazole resistance have been documented, no clear mechanism for metronidazole resistance or a role for plasmids in antimicrobial resistance has been described for CD. Here, we report genome sequences of seven susceptible and sixteen resistant CD isolates from human and animal sources, including isolates from a patient with recurrent CD infection by a PCR ribotype (RT) 020 strain, which developed resistance to metronidazole over the course of treatment (minimal inhibitory concentration [MIC] = 8 mg L).
View Article and Find Full Text PDFis the main causative agent of antibiotic-associated diarrhea. Prompt diagnosis is required for initiation of timely infection control measures and appropriate adjustment of antibiotic treatment. The cobas Cdiff assay for use on the cobas Liat system enables a diagnostic result in 20 minutes.
View Article and Find Full Text PDFGenome Location Dictates the Transcriptional Response to PolC Inhibition in .
Antimicrob Agents Chemother
February 2019
Article Synopsis
- The text discusses a dangerous gut pathogen that poses risks in healthcare settings and highlights the need for new antibiotics due to limited treatment options and resistance issues.
- ACX-362E is introduced as a promising new drug in development that targets DNA polymerase specifically in Gram-positive bacteria, showing effectiveness in laboratory and animal studies.
- The research reveals how ACX-362E impacts gene expression, particularly near the origin of replication, indicating that the location of genes in the genome influences how bacteria respond to treatments that inhibit DNA replication.